Lab21 expands genetic testing deal with PGxHealth
This article was originally published in Clinica
Executive Summary
Diagnostic firm Lab21 has extended its partnership with the genomic testing unit of Clinical Data in order to offer its customers a wider range of genetic tests. Cambridge, UK-based Lab21 had an existing licence with Clinical Data’s PGxHealth subsidiary to exclusively market the Familion portfolio of mutation tests in the UK and Ireland, but has now added assays for catecholaminergic polymorphic ventricular tachycardia (CPVT) and hypertrophic cardiomyopathy (HCM) to its remit. The CPVT and HCM assays are compatible with the Familion platform and will also be marketed in the UK and Ireland. Financial terms of the deal were not revealed.
You may also be interested in...
Alere aided by professional diagnostics sales in fourth quarter
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra and Stout to work on expandable interbody device
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe eyes portfolio expansion to help boost molecular diagnostics credentials
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals